Compare Citius Pharmaceuticals Inc (CTXR) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs JD.Com Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.71 (market cap $20.01M), while JD.Com Inc trades at $31.13 (market cap $44.04B). The key difference: JD.Com Inc is far larger — about 2200.9× Citius Pharmaceuticals Inc's market cap, and JD.Com Inc pays a 3.13% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | JD | |
|---|---|---|
Market Cap | $20.01M | $44.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $36.17 |
52-Week Low | $0.48 | $25.19 |
Enterprise Value | $16.23M | $30.10B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JD.com trades at $33.47, up 1.52% today, with a bullish technical setup as price consolidates near recent highs. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue reached $1.31 trillion in 2025. Analyst consensus remains strongly positive with a $38.00 price target, though regulatory scrutiny from EU authorities over the Ceconomy acquisition presents a near-term headwind.
JD offers attractive valuation with a P/S of 0.24 and consistent earnings beats, but faces margin pressure and regulatory risks. Upside potential exists if Q2 2026 results meet high expectations, but investors must weigh competitive pressures in e-commerce and macroeconomic challenges affecting Chinese equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
